Identification of a 16-MTGs Prognostic Signature in Diffuse Large B-Cell Lymphoma

Background. Diffuse large B-cell lymphoma (DLBCL) is one of the largest lymphoma subcategories. Usually, 50%–70% of DLBCL patients can be cured by the standard treatment. But, at least one third have bad prognosis. Based on this situation, the research on DLBCL therapy strategy is still indispensabl...

Full description

Saved in:
Bibliographic Details
Main Authors: Shijun Wang, Xiaoqin Wang, Guixia Li, Pengcheng Feng
Format: Article
Language:English
Published: Wiley 2024-01-01
Series:Analytical Cellular Pathology
Online Access:http://dx.doi.org/10.1155/2024/4619644
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850173438462787584
author Shijun Wang
Xiaoqin Wang
Guixia Li
Pengcheng Feng
author_facet Shijun Wang
Xiaoqin Wang
Guixia Li
Pengcheng Feng
author_sort Shijun Wang
collection DOAJ
description Background. Diffuse large B-cell lymphoma (DLBCL) is one of the largest lymphoma subcategories. Usually, 50%–70% of DLBCL patients can be cured by the standard treatment. But, at least one third have bad prognosis. Based on this situation, the research on DLBCL therapy strategy is still indispensable. Methods. A prognostic signature was built according to the public data and bioinformatics methods, the stability and reliability was assessed and validated. GSEA was performed to explore the difference in different groups. Consensus clustering and immune infiltration analysis were conducted comprehensively. Results. In this work, a signature based on multiple metabolism-associated genes (MTGs) was established, containing 16 MTGs, to predict the prognosis of DLBCL patients. The accuracy and effectiveness of this signature have been verified by three external validation sets. According to the risk formula, DLBCL patients were divided into high- and low-risk groups, and the survival rate of the low-risk group was significantly higher than that of the high-risk group. Furthermore, gene set enrichment analysis (GSEA) demonstrated that beta-alanine metabolism and regulation of actin cytoskeleton signal pathways were enriched in the low-risk group. The actual survival and nomogram-predicted survival matched well both in the training cohort and verification cohorts. Conclusion. In general, our prognostic signature can provide reliable and valuable information for medical workers in predicting the prognosis of DLBCL. A preprint was made available by the research square in the following link: “https://www.researchsquare.com/article/rs-1468741/v2.”
format Article
id doaj-art-d31fb66ef0964c8cbacdbdb3e69cc4e9
institution OA Journals
issn 2210-7185
language English
publishDate 2024-01-01
publisher Wiley
record_format Article
series Analytical Cellular Pathology
spelling doaj-art-d31fb66ef0964c8cbacdbdb3e69cc4e92025-08-20T02:19:51ZengWileyAnalytical Cellular Pathology2210-71852024-01-01202410.1155/2024/4619644Identification of a 16-MTGs Prognostic Signature in Diffuse Large B-Cell LymphomaShijun Wang0Xiaoqin Wang1Guixia Li2Pengcheng Feng3Department of ChemistryDepartment of AnesthesiologyDepartment of Basic MedicineDepartment of Basic MedicineBackground. Diffuse large B-cell lymphoma (DLBCL) is one of the largest lymphoma subcategories. Usually, 50%–70% of DLBCL patients can be cured by the standard treatment. But, at least one third have bad prognosis. Based on this situation, the research on DLBCL therapy strategy is still indispensable. Methods. A prognostic signature was built according to the public data and bioinformatics methods, the stability and reliability was assessed and validated. GSEA was performed to explore the difference in different groups. Consensus clustering and immune infiltration analysis were conducted comprehensively. Results. In this work, a signature based on multiple metabolism-associated genes (MTGs) was established, containing 16 MTGs, to predict the prognosis of DLBCL patients. The accuracy and effectiveness of this signature have been verified by three external validation sets. According to the risk formula, DLBCL patients were divided into high- and low-risk groups, and the survival rate of the low-risk group was significantly higher than that of the high-risk group. Furthermore, gene set enrichment analysis (GSEA) demonstrated that beta-alanine metabolism and regulation of actin cytoskeleton signal pathways were enriched in the low-risk group. The actual survival and nomogram-predicted survival matched well both in the training cohort and verification cohorts. Conclusion. In general, our prognostic signature can provide reliable and valuable information for medical workers in predicting the prognosis of DLBCL. A preprint was made available by the research square in the following link: “https://www.researchsquare.com/article/rs-1468741/v2.”http://dx.doi.org/10.1155/2024/4619644
spellingShingle Shijun Wang
Xiaoqin Wang
Guixia Li
Pengcheng Feng
Identification of a 16-MTGs Prognostic Signature in Diffuse Large B-Cell Lymphoma
Analytical Cellular Pathology
title Identification of a 16-MTGs Prognostic Signature in Diffuse Large B-Cell Lymphoma
title_full Identification of a 16-MTGs Prognostic Signature in Diffuse Large B-Cell Lymphoma
title_fullStr Identification of a 16-MTGs Prognostic Signature in Diffuse Large B-Cell Lymphoma
title_full_unstemmed Identification of a 16-MTGs Prognostic Signature in Diffuse Large B-Cell Lymphoma
title_short Identification of a 16-MTGs Prognostic Signature in Diffuse Large B-Cell Lymphoma
title_sort identification of a 16 mtgs prognostic signature in diffuse large b cell lymphoma
url http://dx.doi.org/10.1155/2024/4619644
work_keys_str_mv AT shijunwang identificationofa16mtgsprognosticsignatureindiffuselargebcelllymphoma
AT xiaoqinwang identificationofa16mtgsprognosticsignatureindiffuselargebcelllymphoma
AT guixiali identificationofa16mtgsprognosticsignatureindiffuselargebcelllymphoma
AT pengchengfeng identificationofa16mtgsprognosticsignatureindiffuselargebcelllymphoma